Clinical Trial Detail

NCT ID NCT04109482
Title Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS.
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Mustang Bio
Indications

aggressive NK-cell leukemia

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Cyclophosphamide + Decitabine + Fludarabine + MB-102

Age Groups: adult senior

No variant requirements are available.